The Global And China Osteoporosis Drugs Market, estimated at USD 15.76 Bn in 2025, is expected to exhibit a CAGR of 3.9% and reach USD 20.6 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Statistics:
The global and China osteoporosis drugs market is estimated to account for US$ 17.1 Bn in terms of value by the end of 2032.
Global and China Osteoporosis Drugs Market: Drivers
Approval and launch of new drugs is expected to propel growth of the global and China osteoporosis drugs market over the forecast period. For instance, in June 2025, BeiGene Co., Ltd. begun commercializing XGEVA (denosumab) in China for the treatment of giant cell tumor of bone.
Global and China Osteoporosis Drugs Market: Opportunities
Clinical trials for development of novel therapeutics is expected to offer lucrative growth opportunities for players in the global and China osteoporosis drugs market. For instance, in July 2025, Entera Bio Ltd. announced receipt of approval from the Institutional Review Boards at the clinical sites for the amendment to its Phase 2 protocol to include the testing of higher doses of EB613 in postmenopausal women with osteoporosis.
Global and China Osteoporosis Drugs Market: Restraints
Adverse effects of osteoporosis drugs are expected to hinder growth of the market. For instance, consumption of ibandronate may lead to back pain, headache, redness or swelling of eyes, diarrhea, flu-like symptoms, nausea or stomach upset, pain in arms or legs, or redness or swelling where Boniva was injected.
Key Takeaways:
The global and China osteoporosis drugs market was valued at USD 15.76 Bn in 2025 and is forecast to reach a value of USD 20.6 Bn by 2032 at a CAGR of 3.9% between 2025 and 2032. Increasing approval and launch of new drugs is expected to propel growth of the global and China osteoporosis drugs market over the forecast period
Hospitals segment held dominant position in the global and China osteoporosis drugs market in 2025, accounting for 45.4% share in terms of value, the growth of the segment is attributed to increasing prevalence of osteoporosis in developed and developing economies during the forecast period.
Market Trends
Major players in the market are focused on approval and launch of biosimilars to branded drugs of osteoporosis. For instance, in May 2025, JHL Biotech Inc. randomized and dosed the first group of subjects in the company's Australian Phase I Clinical Trial of JHL1266, a proposed biosimilar to denosumab, in healthy subjects, in order to evaluate the similarity in pharmacokinetics, pharmacodynamics, and immunogenicity.
The market is witnessing drug recalls. For instance, in March 2025, Taro Pharmaceuticals Inc. recalled five lots of Taro-Zoledronic acid injection 5mg/100ml, used for osteoporosis and Paget's disease, because of the potential presence of particulate matter in the drug.
Global and China Osteoporosis Drugs Market: Competitive Landscape
Major players operating in the global and China osteoporosis drugs market include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
Global and China Osteoporosis Drugs Market: Key Developments
May 2025: Enzo Biochem, Inc. was issued a U.S. patent for methods for producing monoclonal antibodies against specific regions of human Sclerostin, a protein that is a negative regulator of bone growth and an osteoporosis drug target
January 2025: Bone Biologics, a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model
Segmentation
Scope of the report
- Global and China Osteoporosis Drugs Market, By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- Global and China Osteoporosis Drugs Market, By Route of Administration:
-
- Oral
- Injectable
- Others
-
- Global and China Osteoporosis Drugs Market, By Distribution Channel:
-
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
-
- Global and China Osteoporosis Drugs Market, By Region:
- North America
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- U.S.
- Canada
- By Drug Type:
- Latin America
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Type:
- Europe
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest of Europe
- By Drug Type:
- Asia Pacific
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Drug Type:
- China
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Drug Type:
- Middle East
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- GCC Countries
- Israel
- Rest of Middle East
- By Drug Type:
- Africa
- By Drug Type:
- Bisphosphonates
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
- Bisphosphonates
- By Route of Administration
- Oral
- Injectable
- Others
- By Distribution Channel
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
- By Country
- North Africa
- Central Africa
- South Africa
- By Drug Type:
- North America
- Company Profiles
- Merck & Co. *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly
- Procter & Gamble
- Enzo Biochem, Inc.
- Sanofi-Aventis
- Novartis
- Wyeth
- Roche.
- GlaxoSmithKline
- UCB
- Amgen
- BeiGene Co., Ltd.
- Bone Biologics
- Teijin Pharma Limited
- JHL Biotech Inc.
- Keros Therapeutics
- Taro Pharmaceuticals Inc.
- Merck & Co. *
- “*” marked represents similar segmentation in other categories in the respective section.
Contact Us